Ratings SANA AB

Equities

SANION

SE0005794617

Market Closed - Nasdaq Stockholm Other stock markets 11:29:48 2024-04-19 am EDT			5-day change	1st Jan Change
1.85 ^SEK	-1.91%		-3.85%	-53.87%

Mar. 01	Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	MT
Mar. 01	Sector Update: Health Care Stocks Edge Higher Premarket Friday	MT

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past four months, analysts' average price target has been revised downwards significantly.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SANA AB	-53.87%	19.2M	-	D+
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B		B+
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B		B+
ARGENX SE	-1.80%	21.66B		B
BIONTECH SE	-17.75%	20.77B		B+
GENMAB A/S	-6.91%	18.53B		A-
WUXI APPTEC CO., LTD.	-42.00%	16.91B		A-
BEIGENE, LTD.	-28.19%	13.79B		B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B		C+
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes